Tongjitang Chinese Medicines Company reported decent increases in both profits and revenues for its third quarter, but the results were in line with expectations, providing no upside surprises. The report also showed that sales for Xianling Gubao, the company’s flagship product, increased only 2% over the year-earlier quarter. Investors showed their disappointment in the Q3 report by pushing Tongjitang to a 15% loss. In mid-session, Tongjitang was off by $1.75 at $10.00. That price puts Tongjitang exactly back to the level of its IPO, which took place in March. More details...

Stock Symbol: (NYSE:TCM)